The Contract Manufacturing Services Market for Vaccines is Expected to Grow at an Annualized Rate of Over 10%, Claims Roots Analysis

LONDON, Aug. 20, 2019 /PRNewswire/ -- Roots Analysis has announced the addition of the "Vaccine Contract Manufacturing Market (2^nd Edition), 2019- 2030" report to its list of offerings.

Given that vaccine manufacturing requires highly regulated, state-of-the-art technologies, it has become increasingly difficult for stakeholders to establish in-house expertise for large-scale manufacturing of vaccines. Having said that, numerous vaccine developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs); these service providers are consolidating their capabilities and are expanding their respective service portfolios through substantial acquisition activity.

To order this 400+ page report, which features 130+ figures and 125+ tables, please visit this link

Key Market Insights

Over 90 companies, across the globe, presently claim to provide contract manufacturing services for vaccines 

The market landscape is fragmented featuring a mix of companies of all sizes. Majority of such service providers claim to use mammalian cell cultures for vaccine development and production. It is worth highlighting that over 60% of the CMOs are able to accommodate all scales of operation.

Partnership activity in this domain has increased at a CAGR of over 15%, since 2013

In fact, nearly 50% of the deals inked till date, were established post 2016. Majority of these agreements were observed to be focused on manufacturing various types of vaccines. Interestingly, stakeholders are mainly focused on manufacturing vaccines against infectious diseases, followed by oncology and respiratory diseases.

The demand for vaccines was estimated to be over 3 billion doses in 2018, and anticipated to increase

This is expected to be driven by public immunization initiatives and health programs. The report features a detailed forecast of the future demand for vaccines; this analysis is based on several relevant parameters, such as target patient population, dosing frequency, dose strength, type of vaccines and key geographies.

The installed vaccine manufacturing capacity is currently estimated to be over 1.2 million liters

The maximum share belongs to large (more than 1,000 employees) and very large (more than 5,000 employees) companies, representing more than 90% of the overall global capacity. In terms of location, the maximum vaccine manufacturing capacity is installed in Europe.